Toggle navigation
Home
Search
Services
Blog
Contact
About
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter
Idec Pharmaceuticals Corporation, San Diego, CA, United States
Search 10 grants from Peter Brams
Search grants from Idec Pharmaceuticals Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Genomics scientific research support component
Chronic Disease Prevention and Health Promotion Programs
Eastern Cooperative Oncology Group
Drug-Stress Interaction in Pregnancy and Development
Central Jersey AIDS Clinical Studies Group
Recently added grants:
Characterizing Human RPE Cell Proliferation to Advance Endogenous Regeneration
Multiplexed Detection of Mosquito-Borne Viruses at the Point-of-Care
Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapy
Explore the signaling mechanisms of acquired resistance to tyrosine kinase inhibitors in AML
Secretion of mitochondria as a cellular quality control mechanism
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AI036027-02A1
Application #
2072058
Study Section
Special Emphasis Panel (ZRG7-SSS-4 (02))
Project Start
1994-08-15
Project End
1998-04-30
Budget Start
1996-05-01
Budget End
1997-04-30
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Idec Pharmaceuticals Corporation
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92121
Related projects
NIH 1997
R44 AI
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter / Idec Pharmaceuticals Corporation
NIH 1996
R44 AI
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter / Idec Pharmaceuticals Corporation
Comments
Be the first to comment on Peter Brams's grant